These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18398806)

  • 61. Cytokine abnormalities in the etiology of the cardiometabolic syndrome.
    DeMarco VG; Johnson MS; Whaley-Connell AT; Sowers JR
    Curr Hypertens Rep; 2010 Apr; 12(2):93-8. PubMed ID: 20424939
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treating the Inflammatory Core of Metabolic Syndromes.
    EBioMedicine; 2015 Sep; 2(9):1003-4. PubMed ID: 26501087
    [No Abstract]   [Full Text] [Related]  

  • 63. [NF-kB activation as a molecular basis of pathological process by metabolic syndrome].
    Kaĭdashev IP
    Fiziol Zh (1994); 2012; 58(1):93-101. PubMed ID: 22590744
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Migraine, lipid profile, and cardiovascular disease.
    Bigal ME
    Eur J Neurol; 2010 Mar; 17(3):342-3. PubMed ID: 19930446
    [No Abstract]   [Full Text] [Related]  

  • 65. New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease.
    Matsuzaka T; Shimano H
    J Diabetes Investig; 2020 May; 11(3):532-534. PubMed ID: 32232972
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome.
    Sverdlov AL; Figtree GA; Horowitz JD; Ngo DT
    Mediators Inflamm; 2016; 2016():8254590. PubMed ID: 27563174
    [No Abstract]   [Full Text] [Related]  

  • 67. Aldosterone: a cardiometabolic risk hormone?
    Feliciano Pereira P; Eloiza Priore S; Bressan J
    Nutr Hosp; 2014 Dec; 30(6):1191-202. PubMed ID: 25433098
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pathogenesis and pathophysiology of the cardiometabolic syndrome.
    Kirk EP; Klein S
    J Clin Hypertens (Greenwich); 2009 Dec; 11(12):761-5. PubMed ID: 20021538
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preventing and managing cardiometabolic risk: the logic for intervention.
    Pereira MA; Kottke TE; Jordan C; O'Connor PJ; Pronk NP; Carreón R
    Int J Environ Res Public Health; 2009 Oct; 6(10):2568-84. PubMed ID: 20054455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Organokines in disease.
    Chung HS; Choi KM
    Adv Clin Chem; 2020; 94():261-321. PubMed ID: 31952573
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of intermittent fasting on metabolism in men.
    Azevedo FR; Ikeoka D; Caramelli B
    Rev Assoc Med Bras (1992); 2013; 59(2):167-73. PubMed ID: 23582559
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Physical Therapy for Metabolic Syndrome Prevention in Workers: Novel Role of Physical Therapist].
    Satoh T; Nemoto Y; Utumi T; Munakata M
    Nihon Eiseigaku Zasshi; 2016; 71(2):119-25. PubMed ID: 27246150
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Metabolic Syndrome, Type 2 Diabetes, and Cancer: Epidemiology and Potential Mechanisms.
    Ben-Shmuel S; Rostoker R; Scheinman EJ; LeRoith D
    Handb Exp Pharmacol; 2016; 233():355-72. PubMed ID: 25903410
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Insulin-resistance and cardiovascular risk].
    Dei Cas A; Spigoni V; Metra M; Dei Cas L
    G Ital Cardiol (Rome); 2010 Oct; 11(10 Suppl 1):93S-97S. PubMed ID: 21416835
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Weight change, cardiometabolic risk and the impact of antidiabetic medications in type 2 diabetic patients].
    Danchin N; Eschwège E; Bekka S; Krempf M
    Ann Cardiol Angeiol (Paris); 2010 Aug; 59(4):214-20. PubMed ID: 20691966
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension.
    Korolczuk A; Bełtowski J
    Curr Pharm Des; 2017; 23(10):1533-1539. PubMed ID: 28120721
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity.
    El Husseny MW; Mamdouh M; Shaban S; Ibrahim Abushouk A; Zaki MM; Ahmed OM; Abdel-Daim MM
    J Diabetes Res; 2017; 2017():8095926. PubMed ID: 28286779
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Diabetes mellitus and vascular disease: targeting cardiometabolic risk.
    Grant PJ
    Diab Vasc Dis Res; 2008 Mar; 5(1):7-8. PubMed ID: 18398805
    [No Abstract]   [Full Text] [Related]  

  • 79. Comprehensive management of cardiometabolic risk factors.
    Early J
    Clin Cornerstone; 2007; 8(3):69-80. PubMed ID: 18452843
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus.
    Liang W; Ye DD
    Cytokine Growth Factor Rev; 2019 Aug; 48():32-39. PubMed ID: 31229411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.